AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JAN 25 - (NewsRx.com) -- The December 30, 2000, issue of Oncology highlights the updated National Comprehensive Cancer Network (NCCN) breast cancer treatment guidelines featuring a recently approved treatment option for patients with early breast cancer that has spread to their lymph nodes.
The updated guidelines include a chemotherapy treatment known as CEF (cyclophosphamide, epirubicin, and fluorouracil). A landmark trial confirmed that Ellence (epirubicin hydrochloride injection), part of the CEF regimen, increases five-year survival and reduces the risk of cancer recurrence over CMF (cyclophosphamide, methotrexate and fluorouradil), a standard therapy in post-surgical treatment of early breast cancer.
Each year, researchers from the U.S. leading cancer centers under the auspices of the National Comprehensive Cancer Network examine the latest advances in cancer treatment and agree upon specific treatment recommendations. These treatment guidelines serve as the recommended standards of care for the cancer community. The addition of CEF provides another proven treatment option for women whose breast cancer has spread to the lymph nodes.
"These (NCCN) guidelines are evidence-based. The inclusion of this option for women with breast cancer is a result of a comprehensive body of data that demonstrate the efficacy of epirubicin in treating early stage breast cancer. Epirubicin presents a new treatment option in the United States for early breast cancer patients," stated Robert Carlson, MD, NCCN.
The guidelines for physicians are also accompanied by treatment guidelines that have been rewritten for patients (Breast Cancer Treatment Guidelines for Patients, Version III). Available ...